Literature DB >> 30819933

Regulation of cell migration by α4 and α9 integrins.

Willow Hight-Warburton1, Maddy Parsons2.   

Abstract

Integrins are heterodimeric transmembrane receptors that play an essential role in enabling cells to sense and bind to extracellular ligands. Activation and clustering of integrins leads to the formation of focal adhesions at the plasma membrane that subsequently initiate signalling pathways to control a broad range of functional endpoints including cell migration, proliferation and survival. The α4 and α9 integrins form a small sub-family of receptors that share some specific ligands and binding partners. Although relatively poorly studied compared with other integrin family members, emerging evidence suggests that despite restricted cell and tissue expression profiles, these integrins play a key role in the regulation of signalling pathways controlling cytoskeletal remodelling and migration in both adherent and non-adherent cell types. This review summarises the known shared and specific roles for α4 and α9 integrins and highlights the importance of these receptors in controlling cell migration within both homeostatic and disease settings.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  cell adhesion; cell migration; cytoskeleton; integrins; signalling

Year:  2019        PMID: 30819933     DOI: 10.1042/BCJ20180415

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  7 in total

1.  FGF2-induced PI3K/Akt signaling evokes greater proliferation and adipogenic differentiation of human adipose stem cells from breast than from abdomen or thigh.

Authors:  Guan-Ming Lu; Yong-Xian Rong; Zhi-Jie Liang; Dong-Lin Hunag; Fang-Xiao Wu; Yan-Fei Ma; Zhi-Zhai Luo; Xin-Heng Liu; Steven Mo; Hong-Mian Li
Journal:  Aging (Albany NY)       Date:  2020-07-24       Impact factor: 5.682

2.  Actin polymerization state regulates osteogenic differentiation in human adipose-derived stem cells.

Authors:  Bing Sun; Rongmei Qu; Tingyu Fan; Yuchao Yang; Xin Jiang; Asmat Ullah Khan; Zhitao Zhou; Jingliao Zhang; Kuanhai Wei; Jun Ouyang; Jingxing Dai
Journal:  Cell Mol Biol Lett       Date:  2021-04-15       Impact factor: 5.787

3.  Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.

Authors:  Chaim Gilon; Michal Klazas; Adi Lahiani; Adi Schumacher-Klinger; Shira Merzbach; Johnny N Naoum; Haim Ovadia; Limor Rubin; Susan Cornell-Kennon; Erik M Schaefer; Jehoshua Katzhendler; Cezary Marcinkiewicz; Amnon Hoffman; Philip Lazarovici
Journal:  JACS Au       Date:  2021-11-24

4.  α4/α9 Integrins Coordinate Epithelial Cell Migration Through Local Suppression of MAP Kinase Signaling Pathways.

Authors:  Willow Hight-Warburton; Robert Felix; Andrew Burton; Hannah Maple; Magda S Chegkazi; Roberto A Steiner; John A McGrath; Maddy Parsons
Journal:  Front Cell Dev Biol       Date:  2021-11-25

5.  Integrin α4 up-regulation activates the hedgehog pathway to promote arsenic and benzo[α]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis.

Authors:  Jie Xie; Ping Yang; Hsuan-Pei Lin; Yunfei Li; Marco Clementino; William Fenske; Chengfeng Yang; Chunhong Wang; Zhishan Wang
Journal:  Cancer Lett       Date:  2020-08-26       Impact factor: 9.756

6.  Dragon's Blood Regulates Rac1-WAVE2-Arp2/3 Signaling Pathway to Protect Rat Intestinal Epithelial Barrier Dysfunction Induced by Simulated Microgravity.

Authors:  Yujuan Li; Shan Liu; Huayan Liu; Yaoyuan Cui; Yulin Deng
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

7.  The Development of Peritoneal Metastasis from Gastric Cancer and Rationale of Treatment According to the Mechanism.

Authors:  Yutaka Yonemura; Haruaki Ishibashi; Akiyoshi Mizumoto; Gorou Tukiyama; Yang Liu; Satoshi Wakama; Shouzou Sako; Nobuyuki Takao; Toshiyuki Kitai; Kanji Katayama; Yasuyuki Kamada; Keizou Taniguchi; Daisuke Fujimoto; Yoshio Endou; Masahiro Miura
Journal:  J Clin Med       Date:  2022-01-17       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.